Journal: Frontiers in Genetics

Article Title: Methylation associated with long- or short-term survival in glioblastoma patients from the Nordic phase 3 trial

doi: 10.3389/fgene.2022.934519

Figure Lengend Snippet: Patients from the Nordic trial included in the study. Patients with good prognostic factors were selected from each treatment arm (temozolomide -TMZ, radiotherapy 34Gy-RT 34Gy, and radiotherapy 60Gy- RT60Gy). Half of the tumors had methylated MGMT promoter (m-MGMT), and half had unmethylated MGMT promoter (u-MGMT). These patients were further divided into long-term survivors (LTS) and short-term survivors (STS). N, number of patients.

Article Snippet: The MGMT methylation status was analyzed with the MDxHealth method, Liège, Belgium, as mentioned in ).

Techniques: Methylation

Journal: Frontiers in Genetics

Article Title: Methylation associated with long- or short-term survival in glioblastoma patients from the Nordic phase 3 trial

doi: 10.3389/fgene.2022.934519

Figure Lengend Snippet: Patient characteristics.

Article Snippet: The MGMT methylation status was analyzed with the MDxHealth method, Liège, Belgium, as mentioned in ).

Techniques: Biomarker Discovery, Methylation

Journal: Frontiers in Genetics

Article Title: Methylation associated with long- or short-term survival in glioblastoma patients from the Nordic phase 3 trial

doi: 10.3389/fgene.2022.934519

Figure Lengend Snippet: Pie charts representing the structural genomic distribution of DMCs discovered in samples with long ( n = 3) and short ( n = 3) survival within the different treatment arms and with specified MGMT promoter methylation status. TSS200, 200 bases upstream transcription start site; TSS1500, 1,500 bases upstream transcription start site; UTR, untranslated region; IGR, intergenic region; 60Gy34Gy, combined RT.

Article Snippet: The MGMT methylation status was analyzed with the MDxHealth method, Liège, Belgium, as mentioned in ).

Techniques: Methylation

Journal: Neuro-oncology Advances

Article Title: Prognostic value of O 6 -methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas

doi: 10.1093/noajnl/vdac030

Figure Lengend Snippet: Summary of Cohort Characteristics and Treatments

Article Snippet: The majority of MGMT gene promoter methylation assays was performed by LabCorp or NeoGenomics Laboratories using bisulfite modification of tumor deoxyribonucleic acid (DNA) and polymerase chain reaction (PCR) to detect CpG methylation.

Techniques: Methylation, Biomarker Discovery

Journal: Neuro-oncology Advances

Article Title: Prognostic value of O 6 -methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas

doi: 10.1093/noajnl/vdac030

Figure Lengend Snippet: Overall survival (OS) outcomes of patients stratified by MGMT promoter methylation status. (A) OS of the entire patient cohort. (B) OS of patients diagnosed with glioblastoma multiforme (GBM). (C) OS of patients diagnosed with anaplastic astrocytoma (AA) and low-grade astrocytoma (LA). (D) OS of patients diagnosed with anaplastic oligodendroglioma (AO) and low-grade oligodendroglioma (LO). (E) OS of patients diagnosed with AA. (F) OS of patients diagnosed with LA. (G) OS of patients diagnosed with AO. (H) OS of patients diagnosed with LO.

Article Snippet: The majority of MGMT gene promoter methylation assays was performed by LabCorp or NeoGenomics Laboratories using bisulfite modification of tumor deoxyribonucleic acid (DNA) and polymerase chain reaction (PCR) to detect CpG methylation.

Techniques: Methylation

Journal: Neuro-oncology Advances

Article Title: Prognostic value of O 6 -methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas

doi: 10.1093/noajnl/vdac030

Figure Lengend Snippet: Multivariate Analysis of OS in Various Pathological Subgroups

Article Snippet: The majority of MGMT gene promoter methylation assays was performed by LabCorp or NeoGenomics Laboratories using bisulfite modification of tumor deoxyribonucleic acid (DNA) and polymerase chain reaction (PCR) to detect CpG methylation.

Techniques:

Journal: Neuro-oncology Advances

Article Title: Prognostic value of O 6 -methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas

doi: 10.1093/noajnl/vdac030

Figure Lengend Snippet: Progression-free survival (PFS) outcomes of patients stratified by MGMT promoter methylation status. (A) PFS of the entire patient cohort. (B) PFS of patients diagnosed with glioblastoma multiforme (GBM). (C) PFS of patients diagnosed with anaplastic astrocytoma (AA) and low-grade astrocytoma (LA). (D) PFS of patients diagnosed with anaplastic oligodendroglioma (AO) and low-grade oligodendroglioma (LO). (E) PFS of patients diagnosed with AA. (F) PFS of patients diagnosed with LA. (G) PFS of patients diagnosed with AO. (H) PFS of patients diagnosed with LO.

Article Snippet: The majority of MGMT gene promoter methylation assays was performed by LabCorp or NeoGenomics Laboratories using bisulfite modification of tumor deoxyribonucleic acid (DNA) and polymerase chain reaction (PCR) to detect CpG methylation.

Techniques: Methylation

Journal: Neuro-oncology Advances

Article Title: Prognostic value of O 6 -methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas

doi: 10.1093/noajnl/vdac030

Figure Lengend Snippet: Multivariate Analysis of PFS in Various Pathological Subgroups

Article Snippet: The majority of MGMT gene promoter methylation assays was performed by LabCorp or NeoGenomics Laboratories using bisulfite modification of tumor deoxyribonucleic acid (DNA) and polymerase chain reaction (PCR) to detect CpG methylation.

Techniques:

Journal: Cancer Imaging

Article Title: Assessment of MGMT promoter methylation status in glioblastoma using deep learning features from multi-sequence MRI of intratumoral and peritumoral regions

doi: 10.1186/s40644-024-00817-1

Figure Lengend Snippet: Segmentation illustration of tumor T1WI and CE-T1WI sequence imaging. Patient a is a 66-year-old male with unmethylated MGMT status, and patient b is a 68-year-old female with methylated MGMT status. The red region represents the NCR, the yellow region represents the ET, and the green region represents the PED

Article Snippet: The inclusion criteria included: (1) comprehensive imaging, pathological, and clinical data; (2) pathological confirmation of glioblastoma (WHO CNS 2021) with a definitive diagnosis of MGMT promoter methylation status (in house method developed by UCSF clinical labs, https://genomics.ucsf.edu/content/mgmt-promoter-methylation-assay ); (3) surgical intervention within one week following MRI examination; and (4) absence of any prior surgical, radiotherapy, or chemotherapy treatments before the MRI examination.

Techniques: Sequencing, Imaging, Methylation

Journal: Cancer Imaging

Article Title: Assessment of MGMT promoter methylation status in glioblastoma using deep learning features from multi-sequence MRI of intratumoral and peritumoral regions

doi: 10.1186/s40644-024-00817-1

Figure Lengend Snippet: Prediction results of MGMT promoter methylation status using different models

Article Snippet: The inclusion criteria included: (1) comprehensive imaging, pathological, and clinical data; (2) pathological confirmation of glioblastoma (WHO CNS 2021) with a definitive diagnosis of MGMT promoter methylation status (in house method developed by UCSF clinical labs, https://genomics.ucsf.edu/content/mgmt-promoter-methylation-assay ); (3) surgical intervention within one week following MRI examination; and (4) absence of any prior surgical, radiotherapy, or chemotherapy treatments before the MRI examination.

Techniques: Methylation

Journal: Frontiers in Oncology

Article Title: AI and High-Grade Glioma for Diagnosis and Outcome Prediction: Do All Machine Learning Models Perform Equally Well?

doi: 10.3389/fonc.2021.601425

Figure Lengend Snippet: Number of patients and label distributions for label-sequence combination.

Article Snippet: We used EntroGen’s MGMT Methylation Detection Kit (MSPCR, Cat. No. MGMT-RT44), a semiquantitative real-time PCR-based essay for detection of MGMT promoter methylation within the DMR2 locus, distinguishing between methylated and non-methylated cytosines.

Techniques:

Journal: Frontiers in Oncology

Article Title: AI and High-Grade Glioma for Diagnosis and Outcome Prediction: Do All Machine Learning Models Perform Equally Well?

doi: 10.3389/fonc.2021.601425

Figure Lengend Snippet: MGMT best results (reported as mean ± standard deviation).

Article Snippet: We used EntroGen’s MGMT Methylation Detection Kit (MSPCR, Cat. No. MGMT-RT44), a semiquantitative real-time PCR-based essay for detection of MGMT promoter methylation within the DMR2 locus, distinguishing between methylated and non-methylated cytosines.

Techniques:

Journal: Frontiers in Oncology

Article Title: AI and High-Grade Glioma for Diagnosis and Outcome Prediction: Do All Machine Learning Models Perform Equally Well?

doi: 10.3389/fonc.2021.601425

Figure Lengend Snippet: Best ROC curve for MGMT prediction: AB classifier with FLAIR sequence on CET ROI.

Article Snippet: We used EntroGen’s MGMT Methylation Detection Kit (MSPCR, Cat. No. MGMT-RT44), a semiquantitative real-time PCR-based essay for detection of MGMT promoter methylation within the DMR2 locus, distinguishing between methylated and non-methylated cytosines.

Techniques: Sequencing

Journal: JAMA Oncology

Article Title: Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma

doi: 10.1001/jamaoncol.2022.5370

Figure Lengend Snippet: A, Kaplan-Meier plot comparing overall survival for patients with newly diagnosed glioblastoma treated with autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) and 1366 contemporaneous matched external control participants (ECPs) treated with standard of care, derived from 5 other contemporaneous matched randomized clinical trials. B, Cox hazard ratios of overall survival in prespecified subgroups of participants receiving DCVax-L or treated with standard of care in external trials. In the age subgroup, there were 50 participants in the DCVax-L group and 45 in the ECP group aged 65 years or greater and 182 and 184, respectively in the younger than 65 years group; in the residual disease subgroup, there were 86 patients in the DCVax-L group and 163 in the ECP group with significant residual disease and 146 and 210, respectively, with minimal residual disease; in the MGMT (O 6 -methylguanine-DNA methyltransferase) subgroup, there were 90 patients in the DCVax-L group and 199 in the ECP group with methylated MGMT and 131 and 349, respectively, with unmethylated MGMT. Subgroup analyses of survival, using the same parameters as the comparator publications, are presented with 95% confidence intervals to facilitate comparisons with the ECP.

Article Snippet: The MGMT (O 6 -methylguanine-DNA methyltransferase) gene promoter methylation status, IDH (isocitrate dehydrogenase) R132 mutation status, and postsurgery minimal (<2 cm 2 ) vs significant (≥2 cm 2 ) residual tumor were determined centrally (LabCorp; Mayo; ICON).

Techniques: Control, Derivative Assay, Clinical Proteomics, Methylation